PTC Therapeutics, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
PTC Therapeutics, Inc. (PTCT) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $57.95 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-06
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $57.95M, a 130.71% increase year-over-year.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $41.78M, a 89.80% increase year-over-year.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $47.89M, a 210.24% increase year-over-year.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $26.44M, a 40.07% increase year-over-year.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $174.07M, a 113.72% increase from fiscal 2016.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $81.45M, a 141.71% increase from fiscal 2015.
- PTC Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $33.70M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $57.95M 10-K · filed 2018-03-06 | $99.73M derived: sum of 2 quarters · filed 2018-03-06 | $147.62M derived: sum of 3 quarters · filed 2018-03-06 | $174.07M 10-K · filed 2018-03-06 |
| 2017-09-30 | $41.78M 10-K · filed 2018-03-06 | $89.67M derived: sum of 2 quarters · filed 2018-03-06 | $116.11M derived: sum of 3 quarters · filed 2018-03-06 | $141.23M derived: sum of 4 quarters · filed 2018-03-06 |
| 2017-06-30 | $47.89M 10-K · filed 2018-03-06 | $74.33M derived: sum of 2 quarters · filed 2018-03-06 | $99.45M derived: sum of 3 quarters · filed 2018-03-06 | $121.47M derived: sum of 4 quarters · filed 2018-03-06 |
| 2017-03-31 | $26.44M 10-K · filed 2018-03-06 | $51.56M derived: sum of 2 quarters · filed 2018-03-06 | $73.57M derived: sum of 3 quarters · filed 2018-03-06 | $89.01M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-12-31 | $25.12M 10-K · filed 2018-03-06 | $47.13M derived: sum of 2 quarters · filed 2018-03-06 | $62.57M derived: sum of 3 quarters · filed 2018-03-06 | $81.45M 10-K · filed 2018-03-06 |
| 2016-09-30 | $22.01M 10-K · filed 2018-03-06 | $37.45M derived: sum of 2 quarters · filed 2018-03-06 | $56.33M derived: sum of 3 quarters · filed 2018-03-06 | |
| 2016-06-30 | $15.44M 10-K · filed 2018-03-06 | $34.31M derived: sum of 2 quarters · filed 2018-03-06 | ||
| 2016-03-31 | $18.88M 10-K · filed 2018-03-06 | |||
| 2015-12-31 | $33.70M 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |